Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04425538 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
A Phase 2 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04425538 is a Phase 2 study that has completed, run by Tufts Medical Center. The registered enrollment target is 17 participants.
The verdict
NCT04425538, a Phase 2 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The investigators hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19. Observations from this study will inform the conduct of prospective randomized controlled studies to follow.
Interventions
- DRUG Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04425538
The ClinicalTrials.gov registry entry for NCT04425538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infliximab is the first listed.
NCT04425538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04425538 about?
NCT04425538 is a clinical study titled "A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).". The investigators hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single cen...
What is the current status of trial NCT04425538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2020-06-01. Estimated completion is 2021-01-22.
What interventions are being tested in trial NCT04425538?
The interventions under investigation include: Infliximab (DRUG).
Who is sponsoring clinical trial NCT04425538?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.